1. Purcell K, Fergie J. Epidemic of community-acquired methicillin-resistant Staphylococcus aureus infections: a 14-year study at Driscoll Children’s Hospital. Arch Pediatr Adolesc Med. 2005;159(10):980–5.
2. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae, 2010. Centers for Disease Control and Prevention; 2011 [Cited Aug 4/2012]. Available from: http://www.cdc.gov/abcs/reports-findings/survreports/spneu10.pdf .
3. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae, 2003. Centers for Disease Control and Prevention; 2004 [Cited Aug 4/2012]. Available from: http://www.cdc.gov/abcs/reports-findings/survreports/spneu03.pdf .
4. Ebert S, Leggett J, Vogelman B. In vivo cidal activity and pharmacokinetics parameters (PKPs) for vancomycin against methicillin-susceptible (MSSA) and -resistant (MRSA) S.aureus. In: Program and abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy (New York). Washington: American Society for Microbiology; 1987. p. 173.
5. Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66(1):82–98.